Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab.
Journal
The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
09
09
2020
revised:
09
01
2021
accepted:
15
01
2021
pubmed:
2
2
2021
medline:
24
11
2021
entrez:
1
2
2021
Statut:
ppublish
Résumé
Cellular sources of IL-23 and IL-17A driving skin inflammation in psoriasis remain unclear. Using high-dimensional unsupervised flow cytometry analysis, mononuclear phagocytes and T cells were examined in the same lesions of patients before and during guselkumab (IL-23p19 blocker) or secukinumab (IL-17A blocker) treatment. Among CD11c
Identifiants
pubmed: 33524368
pii: S0022-202X(21)00032-4
doi: 10.1016/j.jid.2021.01.005
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
guselkumab
089658A12D
secukinumab
DLG4EML025
Types de publication
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1707-1718.e9Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.